Editor's note: Seeking Alpha is proud to welcome Ethan Campbell as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click
Tandem Diabetes Care: Strong Financials And Revenue, Overpenalized For Missed Earnings
Summary
- TNDM revenue continues to grow as the company increases market share in an expanding industry.
- Mixed Q4 2021 and Q1 2022 earnings, coupled with the overall market downturn, have created an extremely low valuation relative to its high-growth peers.
- A valuation more similar to its peers yields a 12-month price target of ~$127.
Studying Finance and Accounting at Georgetown University's McDonough School of Business
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.